(NASDAQ: NYXH) Nyxoah Sa's forecast annual revenue growth rate of 143.83% is forecast to beat the US Medical Instruments & Supplies industry's average forecast revenue growth rate of 8.54%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Nyxoah Sa's revenue in 2025 is $5,736,046.On average, 3 Wall Street analysts forecast NYXH's revenue for 2025 to be $312,699,901, with the lowest NYXH revenue forecast at $269,162,252, and the highest NYXH revenue forecast at $368,366,698. On average, 3 Wall Street analysts forecast NYXH's revenue for 2026 to be $1,405,932,896, with the lowest NYXH revenue forecast at $953,485,751, and the highest NYXH revenue forecast at $2,006,550,304.
In 2027, NYXH is forecast to generate $3,296,769,637 in revenue, with the lowest revenue forecast at $3,267,757,016 and the highest revenue forecast at $3,325,782,258.